Phase I Clinical Study of HRS-2189 in the Treatment of Patients With Advanced Malignant Tumors
Status:
Not yet recruiting
Trial end date:
2025-12-31
Target enrollment:
Participant gender:
Summary
This study is a multi center, open label, dose increasing/dose expanding/efficacy expanding
phase I clinical trial aimed at evaluating the safety, tolerance, PK characteristics, and
anti-tumor efficacy characteristics of HRS-2189 single drug in patients with advanced
malignant solid tumors. This study was divided into three stages: dose escalation, dose
expansion, and efficacy expansion.